Physician profile
Eldere Germain
NPI 1467019109
$5,479.19
in general payments reported to CMS, 2019-2025
32 companies · $1,643 in 2025
The $1,643 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $156 · 2021: $305 · 2022: $845 · 2023: $1,293 · 2024: $1,237 · 2025: $1,643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,154 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,154.04 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,018.94 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $746.32 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $513.05 | 2022-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $497.42 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $421.79 | 2022-2025 | |
| Pfizer INC. | $402.53 | 2020-2025 | |
| Abbvie INC. | $302.49 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.10 | 2022-2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $171.03 | 2025 | Uptravi, Opsumit, Opsynvi |
| Avadel Cns Pharmaceuticals, LLC | $155.90 | 2025 | Lumryz |
| C2n Diagnostics, LLC | $130.66 | 2025 | Precivityad2 |
| Lilly USA, LLC | $123.62 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $120.00 | 2023 | Veozah |
| Grifols USA, LLC | $72.07 | 2024 | Prolastin-C Liquid |
| Otsuka America Pharmaceutical, INC. | $70.46 | 2023 | Rexulti, Jynarque |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $62.89 | 2023-2024 | |
| Viatris Specialty LLC | $47.64 | 2025 | Yupelri |
| Redhill Biopharma INC. | $38.35 | 2020 | |
| Sanofi-Aventis U.S. LLC | $37.02 | 2022 | |
| Averitas Pharma INC. | $33.97 | 2023-2024 | Qutenza |
| Shield Therapeutics INC | $32.01 | 2024-2025 | |
| Dexcom, INC. | $31.91 | 2022-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $31.81 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $30.29 | 2023 | Quviviq |
| Exact Sciences Corporation | $28.34 | 2024 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $24.09 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $23.54 | 2025 | General - Pain Management |
| Vifor Pharma, INC. | $23.46 | 2023 | Veltassa |
| Watermark Medical, INC. | $19.67 | 2024 | |
| Corcept Therapeutics | $18.21 | 2025 | Korlym |
| Teva Pharmaceuticals USA, INC. | $15.30 | 2021 | |
| Mylan Specialty L.P. | $13.31 | 2024 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eldere Germain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.